In a dose-escalation trial at the National Cancer Institute, 18 patients with recurrent EGFRvIII-positive glioblastoma were treated by intravenous infusion of up to ≥1010 autologous T cells carrying an EGFRvIII-specific third-generation CAR together with IL-2 after conditioning by lymphodepleting chemotherapy (116). The gene discussed is IL2; the disease is glioblastoma.